Comparison of the corneal effects of latanoprost, fixed combination latanoprost–timolol, and timolol: A double-masked, randomized, one-year study☆
Section snippets
Subjects and methods
The study was a parallel, randomized, double-masked, active-controlled, 1-year multicenter trial conducted at 22 sites throughout the United States. The study protocol and amendments were approved by an institutional review board at each study center. The study was performed in accordance with the ethical principles as described in the Declaration of Helsinki. Before enrollment subjects received information regarding the study, and written informed consent was obtained from each subject.
Results
Three hundred sixty-nine subjects with a mean age of 61 years were enrolled in the study: 127 in the latanoprost group, 116 in the FC group, and 126 in the timolol group (Table 1). The subjects were predominantly white (73%), with an equal number of men and women. The groups did not differ regarding age, gender, race, or baseline IOP. The baseline central endothelial cell density and corneal thickness were similar among the three groups. In 61% of subjects the diagnosis was primary open-angle
Discussion
Latanoprost has proven to be a safe and effective agent for lowering IOP in the management of ocular hypertension and open-angle glaucoma.1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 However, the drug has manifested external (eyelash darkening, thickening, and lengthening) and anterior segment (iridial pigmentation) side effects. A few cases of herpes simplex virus keratitis during latanoprost treatment have been reported, but the role of latanoprost, if any, is still unknown.19, 20, 21, 22 A short-term
Latanoprost corneal effects study group
John Burchfield, Rochester, NY
Claude Burgoyne, New Orleans, LA
Edward Burney, Cleveland, OH
Harvey DuBiner, Morrow, GA
Marvin Greenberg, Tamarac, FL
Ronald Gross, Houston, TX
Ramel Hemady, Baltimore, MD
Phillip Hessberg, Grosse Pointe Park, MI
David Karp, Louisville, KY
Michael Kottler, Salt Lake City, UT
Theodore Krupin, Chicago, IL
Sayoko Moroi, Ann Arbor, MI
Robert Noecker, Tucson, AZ
Charles Ostrov, Minneapolis, MN
Joel Schuman, Boston, MA
Elizabeth Sharpe, Mount Pleasant, SC
Mark Sherwood, Gainesville, FL
References (37)
- et al.
Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. The Scandinavian Latanoprost Study Group
Ophthalmology
(1995) - et al.
A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group
Ophthalmology
(1996) Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. The United States Latanoprost Study Group
Ophthalmology
(1996)- et al.
Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. The Latanoprost Study Group
Ophthalmology
(1996) - et al.
Latanoprost treatment for glaucomaeffects of treating for 1 year and of switching from timolol. The United States Latanoprost Study Group
Am J Ophthamol
(1998) Latanoprost. Two years’ experience of its use in the United Kingdom. The Latanoprost Study Group
Ophthalmology
(1998)- et al.
A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma
Ophthalmology
(1999) - et al.
Effects of PhXA41, a new prostaglandin F2α analog, on aqueous humor dynamics in human eyes
Ophthalmology
(1993) - et al.
Effects of topical timolol on corneal endothelial cell morphology in vivo
Am J Ophthalmol
(1983) - et al.
Corneal endothelial changes in ocular hypertensive individuals after long-term unilateral treatment with timolol
Am J Ophthalmol
(1990)
Latanoprost and herpes simplex keratitis
Am J Ophthalmol
Central corneal endothelial cell density and central corneal thickness in ocular hypertension and primary open-angle glaucoma
Am J Ophthalmol
Corneal endothelial changes in primary acute angle-closure glaucoma
Ophthalmology
The corneal endothelium after laser therapy for glaucoma
Am J Ophthalmol
Effects of argon laser iridotomy on the corneal endothelium
Am J Ophthalmol
The effects of Nd:YAG laser iridotomy on the corneal endothelium
Am J Ophthalmol
Corneal endothelial cell counts after Molteno implantation
Am J Ophthalmol
A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study
Arch Ophthalmol
Cited by (89)
Topical glaucoma medications – Clinical implications for the ocular surface
2022, Ocular SurfaceCitation Excerpt :When glaucomatous subjects treated with various PC PGAs were compared to healthy controls, the glaucoma group demonstrated lower keratocyte density and decreased central corneal thickness (515.2 vs 549.6 μm) measured with IVCM [51]. However, a prospective randomized study including 369 glaucoma patients treated with either latanoprost, timolol or latanoprost/timolol fixed combination (FC) for 12 months found no changes in corneal endothelial cell density or central corneal thickness [52]. A prospective study including 66 patients treated with latanoprost and 42 patients treated with latanoprost and timolol (preservative status not described) reported a significant increase in central corneal thickness and corneal hysteresis but no change in corneal resistance factor [53].
Effects of Netarsudil on the Corneal Endothelium: Three-Month Findings from a Phase 3 Trial
2020, Ophthalmology GlaucomaCitation Excerpt :The OHTS data revealed no effect of topical IOP-lowering medications on ECD.21 An analysis of approximately 20 000 eye bank eyes also found no differences in ECD of corneas from donors who did and did not use topical glaucoma medications; further analysis found no effect of any specific drug class (prostaglandin, beta-blocker, carbonic anhydrase inhibitor, alpha agonist, or miotic) and no effect of single versus multiple medication use.23-25 Of note, there were no ROCK inhibitors approved for use in the United States during the time that these studies were conducted.
Influence of applied corneal endothelium image segmentation techniques on the clinical parameters
2017, Computerized Medical Imaging and GraphicsThe effect of corneal biomechanical properties on rebound tonometer in patients with normal-tension glaucoma
2015, American Journal of OphthalmologyCitation Excerpt :Some controversy exists concerning the effect of chronic medication use on corneal biomechanics. A prospective study reported that there was no change in the mean percent change in corneal thickness in the latanoprost and timolol group.33 Another study revealed that corneal hysteresis was comparable in the treated eyes and the untreated eyes and was not significantly different in the eyes receiving a prostaglandin analogue.34
Therapeutic uses of prostaglandin F<inf>2α</inf> analogues in ocular disease and novel synthetic strategies
2013, Prostaglandins and Other Lipid MediatorsGlaucoma-associated corneal endothelial cell damage: A review
2018, Survey of Ophthalmology
- ☆
Supported by Pharmacia Corporation, Uppsala, Sweden, and in part by the Ohio Lions Eye Research Foundation, Columbus, Ohio, and Research to Prevent Blindness, New York, New York.
- 1
Gina Eriksson and Lisa Osterling were employees of Pharmacia Corporation. The other authors have no proprietary interest in latanoprost or Pharmacia. Ms. Eriksson is now with Quintiles AB, Uppsala, Sweden.